Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

Detaylı Bibliyografya
Asıl Yazarlar:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2002

Benzer Materyaller

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Yazar:: Eaton, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Yazar:: Eaton, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Role of osteoprotegerin (OPG) in cancer.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

The role of osteoprotegerin in breast and prostate cancer
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
Yazar:: Holen Ingunn, ve diğerleri
Baskı/Yayın Bilgisi: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
Yazar:: Lili Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
Yazar:: Gamal B Mohamed, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Yazar:: Waterman, E, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
Yazar:: Miles, L, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
Yazar:: Noura N. Alraouji, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
Yazar:: Riham Eid, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
Yazar:: Siamak Kazemi-Sufi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
Yazar:: Nyambo, R, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Yazar:: Nyambo, R, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
Yazar:: Chan Kai-Ming, ve diğerleri
Baskı/Yayın Bilgisi: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
Yazar:: Syed Muhammad Muneeb Akhtar, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
Yazar:: Yao Jing, ve diğerleri
Baskı/Yayın Bilgisi: (2011-03-01)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
Yazar:: Saba Tariq, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Yazar:: Yosra Azizpour, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Yazar:: Yosra Azizpour, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
Yazar:: Ruffion, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
Yazar:: Lara Absil, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
Yazar:: Indra Wijaya, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
Yazar:: Shirly Elisa Tedjasaputra, ve diğerleri
Baskı/Yayın Bilgisi: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
Yazar:: Salvador Atilano-Miguel, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
Yazar:: Lane Denis, ve diğerleri
Baskı/Yayın Bilgisi: (2012-11-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Yazar:: Martin Widschwendter, ve diğerleri
Baskı/Yayın Bilgisi: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
Yazar:: Cross, N, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
Yazar:: Cross, N, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Yazar:: Vanderkerken, K, ve diğerleri
Baskı/Yayın Bilgisi: (2003)